15 September 2023 in EBioMedicine
Genomic characterisation has led to an improved understanding of adult melanoma. However, the aetiology of melanoma in children is still unclear and identifying the correct diagnosis and therapeutic strategies remains challenging. Exome sequencing of matched tumour-normal pairs from 26 paediatric patients was performed to study the mutational spectrum of melanomas. The cohort was grouped into different categories: spitzoid melanoma (SM), conventional melanoma (CM), and other melanomas (OT). In all patients with CM (n = 10) germline variants associated with melanoma were found in low to moderate melanoma risk genes: in 8 patients MC1R variants, in 2 patients variants in MITF, PTEN and BRCA2. Somatic BRAF mutations were detected in 60% of CMs, homozygous deletions of CDKN2A in 20%, TERTp mutations in 30%. In the SM group (n = 12), 5 patients carried at least one MC1R variant; somatic BRAF mutations were detected in 8.3%, fusions in 25% of the cases. No SM showed a homozygous CDKN2A deletion nor a TERTp mutation. In 81.8% of the CM/SM cases the UV damage signatures SBS7 and/or DBS1 were detected. The patient with melanoma arising in giant congenital nevus (CNM) demonstrated the characteristic NRAS Q61K mutation. UV-radiation and MC1R germline variants are risk factors in the development of conventional and spitzoid paediatric melanomas. Paediatric CMs share genomic similarities with adult CMs while the SMs differ genetically from the CM group. Consistent genetic characterization of all paediatric melanomas will potentially lead to better subtype differentiation, treatment, and prevention in the future. Found in Acknowledgement.
8 November 2022 in European Journal of Cancer
2 June 2025 in Pediatric Blood & Cancer
Background: Colorectal cancer (CRC) accounts for 10% of cancer cases worldwide; however, pediatric CRC is extremely rare, with an annual incidence of one to two cases per million. Microsatellite instability (MSI) has been shown to play a relevant prognostic role in adult CRC. Corresponding data for pediatric CRC are lacking. This study examines MSI in pediatric CRC.Procedure: Patient‐, tumor‐, and treatment‐related data of patients less than 18 years with CRC enrolled in the German Registry for Rare Pediatric Tumors (STEP) between 2005 and 2023 were analyzed and compared with data on patients less than 30 years with CRC and known MSI status from the Surveillance, Epidemiology, and End Results Program (SEER).Results: Forty‐one patients with CRC were recorded in STEP. Cancer predisposition syndromes were identified in 52% of tested cases, especially in CRC with MSI (84.6%). The SEER cohort included 803 CRC patients under 30 years, 52 of whom were under 20 years. Most cases were at an advanced stage at diagnosis, with localized disease being rare (STEP: 4.9%, SEER: 16.4%). The 5‐year overall survival (OS) of STEP patients was 47.9% ± 9.7%. MSI was observed in 37.5% (STEP) and 32.7% (SEER <20 years) of patients. CRCs with MSI had lower rates of distant metastases and were associated with a significantly better survival (STEP 5‐year OS: MSI 85.1% ± 9.7% vs. no‐MSI 28.3% ± 11.2%, p = 0.007).Conclusions: While pediatric CRCs overall more often demonstrate advanced stages, unfavorable histology, and a poorer prognosis than adult CRC, MSI is more common in pediatric CRC and is associated with superior survival.
14 August 2026 in Prenatal Diagnosis
Objective: To present the prenatal sonographic features, genomic findings, and pregnancy outcomes of fetuses with biallelic pathogenic RNU4ATAC variants linked to microcephalic osteodysplastic primordial dwarfism type I (MOPD1). Methods: This retrospective case series includes five prenatal cases with MOPD1. Diagnoses were established by prenatal ultrasound and genetic testing. Genome sequencing (GS) or targeted exome sequencing (ES) detected the variants either prenatally or after termination of pregnancy (TOP). Clinical data including parental demographics, ultrasound findings, and pregnancy outcomes were collected. Results: All fetuses presented with consistent anomalies on ultrasound including intrauterine growth restriction (IUGR), microcephaly, agenesis of the corpus callosum (ACC), intracranial cysts, lissencephaly, and micrognathia. IUGR was the earliest anomaly detected in all five cases. Prenatal ultrasound findings suggestive of skeletal dysplasia were identified in one case. All cases carried biallelic pathogenic RNU4ATAC variants associated with MOPD1. TOP was chosen in four cases. One fetus was delivered at 39 + 1 weeks with genetic diagnosis confirmed at 27 weeks. Conclusion: IUGR, microcephaly and ACC can be detected in fetuses with MOPD1 at around 18 weeks of gestation. Interestingly, skeletal dysplasia was not a consistent prenatal finding. Variants in the non‐coding RNU4ATAC gene need to be detected by GS or targeted approaches beyond standard ES.